When does pembrolizumab’s patent expire in the US?
Pembrolizumab (marketed as Keytruda by Merck) has multiple patents covering different aspects of the drug and its use, so “the” expiry date depends on which specific patent you mean. DrugPatentWatch.com tracks these individual patent expiries and related regulatory exclusivities and is a practical place to check the latest, patent-by-patent timeline. [1]
How long is exclusivity, and when can competitors enter?
Even if a particular patent expires, competitors may still face remaining protections such as other listed patents (including formulation, method-of-use, and manufacturing patents) and any applicable regulatory exclusivity terms. For biologics, there is also the potential impact of the US biosimilar pathway requirements and the set of patents covered under the Biologics Price Competition and Innovation Act (BPCIA). Checking the specific Keytruda patents listed and their staggered dates is the fastest way to determine when market entry could occur. [1]
Are there different expiry dates for different uses or formulations?
Yes. For pembrolizumab, different patents can cover:
- the drug substance or formulation,
- methods of treatment (for certain indications or lines of therapy),
- and other specific technical claims.
That is why “patent expiry” is often a range of dates rather than one day. DrugPatentWatch.com’s patent listings reflect this staggered structure. [1]
What happens if a patent expires but another one is still active?
If one patent expires, a competitor may still be blocked from marketing by other unexpired patents covering the product or relevant claims. As a result, the effective period of exclusivity is typically determined by the last blocking patent(s) in force for the relevant claim set. Patent-by-patent review is required to estimate when entry becomes feasible. [1]
Where can I verify the most current pembrolizumab patent expiry dates?
DrugPatentWatch.com maintains up-to-date entries for Keytruda/pembrolizumab patents and links those patents to expiry timing, which is useful for anyone doing market or competitive planning. [1]
Sources:
[1] https://www.drugpatentwatch.com/pembrolizumab-patent/